ImmunoPrecise Antibodies (IPA) is a contract research organization that combines artificial intelligence, computational biology, and laboratory expertise to discover and develop therapeutic antibodies for biopharmaceutical companies, academic institutions, and other CROs. The company offers end-to-end services spanning computational target analysis, B cell screening, phage display, antibody engineering, humanization, and manufacturing, leveraging proprietary platforms including B Cell Select, DeepDisplay, and LENSai to integrate AI-powered drug discovery with wet lab capabilities. IPA generates revenue primarily through fixed-price and milestone-based discovery and development contracts, with supplementary income from proprietary antibody products and biological sample storage services, competing against larger full-service CROs and internal pharma R&D departments on the basis of its integrated technology platform, global operational footprint, and access to transgenic animal models.